Effect of Paroxetine on the Neuropathic Pain: A Molecular Study.


Journal

Iranian biomedical journal
ISSN: 2008-823X
Titre abrégé: Iran Biomed J
Pays: Iran
ID NLM: 9814853

Informations de publication

Date de publication:
09 2020
Historique:
entrez: 21 5 2020
pubmed: 21 5 2020
medline: 28 7 2021
Statut: ppublish

Résumé

Neuropathic pain, due to peripheral nerve damage, has influenced millions of people living all over the world. It has been shown that paroxetine can relieve neuropathic pain. Recently, the role of certain proteins like brain-derived neurotrophic factor (BDNF), GABAA receptor, and K+-Cl- cotransporter 2 (KCC2) transporter in the occurrence of neuropathic pain has been documented. In the current study, the expression of these proteins affected by paroxetine was evaluated. Male Wistar rats were allocated into two main groups of pre- and post-injury. Rats in each main group received paroxetine before nerve injury and at day seven after nerve damage till day 14, respectively. The lumbar spinal cord of animals was extracted to assess the expression of target genes and proteins. In the preventive study, paroxetine decreased BDNF and increased KCC2 and GABAA gene and protein expression, while in the post-injury paradigm, it decreased BDNF and increased KCC2 genes and protein expression. In this regard, an increase in the protein expression of GABAA was observed. It seems that paroxetine with a change in the expression of three significant proteins involved in neuropathic pain could attenuate this type of chronic pain.

Sections du résumé

Background
Neuropathic pain, due to peripheral nerve damage, has influenced millions of people living all over the world. It has been shown that paroxetine can relieve neuropathic pain. Recently, the role of certain proteins like brain-derived neurotrophic factor (BDNF), GABAA receptor, and K+-Cl- cotransporter 2 (KCC2) transporter in the occurrence of neuropathic pain has been documented. In the current study, the expression of these proteins affected by paroxetine was evaluated.
Methods
Male Wistar rats were allocated into two main groups of pre- and post-injury. Rats in each main group received paroxetine before nerve injury and at day seven after nerve damage till day 14, respectively. The lumbar spinal cord of animals was extracted to assess the expression of target genes and proteins.
Results
In the preventive study, paroxetine decreased BDNF and increased KCC2 and GABAA gene and protein expression, while in the post-injury paradigm, it decreased BDNF and increased KCC2 genes and protein expression. In this regard, an increase in the protein expression of GABAA was observed.
Conclusion
It seems that paroxetine with a change in the expression of three significant proteins involved in neuropathic pain could attenuate this type of chronic pain.

Identifiants

pubmed: 32429644
doi: 10.29252/ibj.24.5.301
pmc: PMC7392138
doi:

Substances chimiques

Aif1 protein, rat 0
Brain-Derived Neurotrophic Factor 0
Calcium-Binding Proteins 0
Microfilament Proteins 0
Receptors, GABA-A 0
Symporters 0
Paroxetine 41VRH5220H

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

306-13

Références

J Pharmacol Exp Ther. 1994 Oct;271(1):76-82
pubmed: 7965759
J Neurosci. 2009 Mar 18;29(11):3518-28
pubmed: 19295157
Curr Top Med Chem. 2005;5(6):547-55
pubmed: 16022677
Brain Behav Immun. 2007 Jul;21(5):642-51
pubmed: 17174525
Neuroscience. 2001;104(2):569-82
pubmed: 11377856
Brain Res. 2008 Jul 11;1219:116-26
pubmed: 18538310
J Biomed Mater Res. 2000 Dec 5;52(3):460-6
pubmed: 11007613
J Pain. 2004 Nov;5(9):491-7
pubmed: 15556827
Iran Biomed J. 2014;18(2):94-100
pubmed: 24518550
Brain Res Rev. 2008 Jan;57(1):103-10
pubmed: 17949820
Glia. 2009 Nov 1;57(14):1469-79
pubmed: 19306358
Brain Res. 1991 Nov 22;565(1):1-7
pubmed: 1723019
J Neurosci. 2000 Oct 15;20(20):7531-8
pubmed: 11027211
Trends Neurosci. 2003 Apr;26(4):199-206
pubmed: 12689771
Pain. 1998 Oct;78(1):13-26
pubmed: 9822208
Mol Pain. 2011 Feb 23;7:16
pubmed: 21345196
Pain. 2001 Feb 1;90(1-2):1-6
pubmed: 11166964
Prog Neurobiol. 2008 Jul;85(3):297-317
pubmed: 18514997
Life Sci. 2003 Dec 5;74(2-3):189-97
pubmed: 14607246
Mol Pain. 2007 Nov 01;3:33
pubmed: 17974036
J Pain. 2007 Jan;8(1):33-50
pubmed: 17207742
J Neurosurg. 2008 Feb;108(2):292-8
pubmed: 18240925
Neuroscience. 2011 Jun 16;184:183-94
pubmed: 21496475
J Physiol. 2008 Dec 1;586(23):5701-15
pubmed: 18845615
Exp Neurol. 2010 Apr;222(2):256-66
pubmed: 20079352
Purinergic Signal. 2012 Sep;8(3):621-8
pubmed: 22528681
Pain. 1979 Oct;7(2):103-11
pubmed: 574931
Exp Neurol. 2012 Apr;234(2):293-301
pubmed: 21946271
News Physiol Sci. 2000 Dec;15:309-312
pubmed: 11390932
J Neurosci. 2003 Sep 24;23(25):8752-8
pubmed: 14507975
Physiol Rev. 2002 Oct;82(4):1013-67
pubmed: 12270951
Nature. 2005 Dec 15;438(7070):1017-21
pubmed: 16355225
Pain. 2003 Jan;101(1-2):65-77
pubmed: 12507701
Neurosci Res. 2006 May;55(1):1-10
pubmed: 16516994
Science. 1986 Jun 13;232(4756):1413-5
pubmed: 2424084
Eur J Pain. 2009 Feb;13(2):138-45
pubmed: 18499488
J Cell Biol. 2002 Dec 9;159(5):747-52
pubmed: 12473684
Annu Rev Neurosci. 2006;29:507-38
pubmed: 16776595
J Gen Physiol. 2010 Apr;135(4):333-53
pubmed: 20231374
Brain Res Rev. 2009 Apr;60(1):149-70
pubmed: 19167425
Pain. 2008 Jun;136(3):348-55
pubmed: 17822849
Neuroscience. 1987 Feb;20(2):365-83
pubmed: 3035421
Brain Res Mol Brain Res. 1998 Jun 1;57(1):1-9
pubmed: 9630473
Trends Neurosci. 1990 Dec;13(12):499-505
pubmed: 1703681
Pain. 2003 Sep;105(1-2):347-53
pubmed: 14499453
Cell Mol Neurobiol. 2009 Jul;29(5):609-19
pubmed: 19319675
Pain. 2008 Jul 31;137(3):532-9
pubmed: 18063479
Curr Opin Pharmacol. 2007 Feb;7(1):93-9
pubmed: 17182282
Biochem Biophys Res Commun. 1996 Jul 25;224(3):855-62
pubmed: 8713135
Prog Neurobiol. 1994 Mar;42(4):489-537
pubmed: 7522334
Mol Pain. 2008 Sep 17;4:36
pubmed: 18799000

Auteurs

Malek Zarei (M)

Department of Pharmacology, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Masoumeh Sabetkasaei (M)

Department of Pharmacology, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Taraneh Moini-Zanjani (T)

Department of Pharmacology, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH